Clinical Research & Data, Complete Revascularization, Protected PCI
Results From PROTECT III, the Largest Prospective Multi-Center Single-Arm Study
Jeffrey W. Moses, MD, presents results from the PROTECT III study which included 1,143 patients undergoing elective non-emergent PCI with the Impella® heart pump from 45 sites. PROTECT III represents the largest prospective study of the use of Impella mechanical circulatory support for high-risk PCI in the real world with contemporary best practices. From this data, Dr. Moses highlights the following:
- PROTECT III patients were older with more comorbidities and more complex lesions, and underwent more extensive revascularization than PROTECT II patients
- PROTECT III 90-day MACCE rates were improved compared to PROTECT II in both unmatched and propensity matched cohorts
- PROTECT III procedural outcomes show improved in-hospital safety with significantly fewer vascular and bleeding complications compared to PROTECT II
Dr. Moses is the John and Myrna Daniels Professor of Cardiology and director of interventional cardiac therapeutics at Columbia University Medical center as well as the director of complex coronary interventions at St. Francis Hospital in Roslyn, NY.
Continue the Series
Protected PCI in COVID-19 Era: The Rise in Importance of Complete Revascularization
Cindy Grines, MD, FACC, MSCAI discusses best practices for using percutaneous mechanical circulatory support to enable complete revascularization in complex and sick patients, especially during the current COVID-19 era.
Clinical Relevance of Revascularization Extent in Protected PCI: Insight From Italian Studies
Francesco Burzotta, MD, discusses the clinical impact of revascularization extent in Protected PCI.
Rapid and Safe Adoption of the New Single Access Technique
Duane Pinto, MD, MPH discusses the new single access technique, designed to avoid an additional arterial access, and reduce associated complications as well as make the procedure more rapid.